Rose Nikravesh
Psychiatry · Los Angeles, CANPI 1720222847
Payments from drug & device makers
Across 143 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$439
- Takeda Pharmaceuticals U.S.A., Inc.$389
- Vanda Pharmaceuticals Inc.$357
- Otsuka America Pharmaceutical, Inc.$315
- Lundbeck LLC$281
- Johnson & Johnson$217
- plus $936 from 9 others
What the payments were for
- Food & beverage$2,90499%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 25 | $439 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $389 |
| Vanda Pharmaceuticals Inc. | 13 | $357 |
| Otsuka America Pharmaceutical, Inc. | 14 | $315 |
| Lundbeck LLC | 16 | $281 |
| Johnson & Johnson | 8 | $217 |
| Ironshore Pharmaceuticals Inc. | 5 | $201 |
| Neos Therapeutics, LP | 9 | $189 |
| Sunovion Pharmaceuticals Inc. | 11 | $174 |
| Neurocrine Biosciences, Inc. | 1 | $157 |
| Bausch Health US, LLC | 4 | $84 |
| Avanir Pharmaceuticals, Inc. | 2 | $49 |
| Neuronetics, Inc. | 1 | $37 |
| Adlon Therapeutics L.p. | 2 | $27 |
| Merck | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$157
- VRAYLAR$125
- REXULTI$117
- Jornay PM 20mg capsules (Bottle of 100)$114
How this compares
$2,934 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluoxetine Hcl | 27 | $2,687 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $1,416 |
| Buspirone Hcl | 21 | $706 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 23 | $668 |
| Bupropion XlBupropion Hcl | 45 | $471 |
| Escitalopram Oxalate | 22 | $408 |
| Quetiapine Fumarate | 26 | $343 |
| Sertraline Hcl | 30 | $318 |
| Trazodone Hcl | 16 | $203 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 23 | $77 |
| Lamotrigine | 24 | $37 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Los Angeles
- Lon SchneiderLos Angeles$1.8M
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.